Huaren Pharmaceutical: Announcement on Wholly-owned Subsidiaries Obtaining Medical Device Registration Certificates
Huaren Pharmaceutical: Announcement on Wholly-owned Subsidiaries Obtaining Medical Device Registration Certificates
Huaren Pharmaceutical: Announcement on shareholders holding 5% or more of their shares to reduce their holdings by more than 1%
Huaren Pharmaceutical: Announcement on major lawsuits involving the company and its subsidiaries
Huaren Pharmaceutical: Notice on the Wholly-owned Subsidiary Obtaining a Notice of Approval of the Marketing Application for Papaverine Hydrochloride API
Huaren Pharmaceutical: Announcement of Supervisory Committee Resolutions
Huaren Pharmaceutical: Prompt Announcement on the Disclosure of the 2024 Semi-Annual Report
Huaren Pharmaceutical: Announcement on the resignation of the company\'s senior management
Huaren Pharmaceutical: Announcement of Board Resolutions
Huaren Pharmaceutical: Summary table on the use of non-operating capital and other related capital transactions for the first half year of 2024
Huaren Pharmaceutical: 2024 Semi-Annual Report
Huaren Pharmaceutical: 2024 Semi-Annual Report Summary
Huaren Pharmaceutical: Announcement regarding wholly-owned subsidiary obtaining registration certificate for medical instruments.
Huaren Pharmaceutical: Announcement regarding the approval notice for the listing application of the wholly-owned subsidiary's active pharmaceutical ingredient Ketoprofen.
Huaren Pharmaceutical: Announcement regarding the acquisition of pharmaceutical registration certificate for the wholly-owned subsidiary Ketokonkalin Injection.
Huaren Pharmaceutical: Notice on Pre-Disclosure of Shareholding Reduction Plan by Shareholders Holding More Than 5% of Shares
Huaren Pharmaceutical: Announcement regarding wholly-owned subsidiary obtaining registration certificate for medical instruments.
Huaren Pharmaceutical: Announcement of Annual Equity Distribution Implementation in 2023
Huaren Pharmaceutical: Announcement regarding termination of the previous plan for change of controlling shareholder and initiation of a new plan for change of controlling shareholder.
Huaren Pharmaceutical: Announcement regarding the acquisition of pharmaceutical supplementary application approval for peritoneal dialysis solution (lactate-G1.5%, G2.5%).
No Data
No Data